Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Lawrence Dougan, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Michael Dougan and Sienna Durbin.
Connection Strength

1.130
  1. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.897
  2. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.060
  3. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. Eur Radiol. 2021 Dec; 31(12):8868-8878.
    View in: PubMed
    Score: 0.059
  4. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.058
  5. Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. Eur J Cancer. 2021 01; 142:143-146.
    View in: PubMed
    Score: 0.056
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.